Gene Expression Signatures and the Spectrum of Coronary Artery Disease

Journal of Cardiovascular Translational Research

Volumn 8, Issue 6, 2015, Pages 339-352

  Friede, Kevin A ^a   Ginsburg, Geoffrey S ^a,b   Voora, Deepak ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary artery disease; Gene expression profiling; MicroRNA; mRNA

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; HEMOGLOBIN A1C; LISINOPRIL; MESSENGER RNA; METFORMIN; MICRORNA;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CORONARY ARTERY DISEASE; DYSPNEA; ELECTROCARDIOGRAPHY; EXERCISE TEST; GENE EXPRESSION; HEART CATHETERIZATION; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RNA ANALYSIS; T WAVE INVERSION; THORAX PAIN; TREATMENT RESPONSE; WEIGHT GAIN; COMPLICATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; RISK FACTOR;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; RISK FACTORS; RNA, MESSENGER;

EID: 84938740951     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-015-9640-6     Document Type: Article

References (113)

1. Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., et al. (2007). Genomewide association analysis of coronary artery disease. New England Journal of Medicine, 357(5), 443–453. doi:10.1056/NEJMoa072366.
2. Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., et al. (2007). A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science, 316(5830), 1491–1493. doi:10.1126/science.1142842.
3. Shen, G.-Q., Li, L., Rao, S., Abdullah, K. G., Ban, J. M., et al. (2008). Four SNPs on chromosome 9p21 in a South Korean population implicate a genetic locus that confers high cross-race risk for development of coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(2), 360–365.
4. Shen, G.-Q., Rao, S., Martinelli, N., Li, L., Olivieri, O., et al. (2008). Association between four SNPs on chromosome 9p21 and myocardial infarction is replicated in an Italian population. Journal of Human Genetics, 53(2), 144–150.
5. Assimes, T. L., Knowles, J. W., Basu, A., Iribarren, C., Southwick, A., et al. (2008). Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Human Molecular Genetics, 17(15), 2320–2328.
6. Kathiresan, S., Voight, B. F., Purcell, S., Musunuru, K., Ardissino, D., et al. (2009). Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature Genetics, 41(3), 334–341.
7. Johnson, A. D., Hwang, S.-J., Voorman, A., Morrison, A., Peloso, G. M., et al. (2013). Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study. Circulation, 127(7), 799–810. doi:10.1161/circulationaha.112.111559.
8. Shia, W.-C., Ku, T.-H., Tsao, Y.-M., Hsia, C.-H., Chang, Y.-M., et al. (2011). Genetic copy number variants in myocardial infarction patients with hyperlipidemia. BMC Genomics, 12(Suppl 3), S23.
9. Ripatti, S., Tikkanen, E., Orho-Melander, M., Havulinna, A. S., Silander, K., et al. (2010). A multilocus genetic risk score for coronary heart disease: case–control and prospective cohort analyses. The Lancet, 376(9750), 1393–1400. doi:10.1016/S0140-6736(10)61267-6.
10. Aziz, H., Zaas, A., & Ginsburg, G. S. (2007). Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Medecine, 1(3–4), 105–112.
11. Suresh, R., Li, X., Chiriac, A., Goel, K., Terzic, A., et al. (2014). Transcriptome from circulating cells suggests dysregulated pathways associated with long-term recurrent events following first-time myocardial infarction. Journal of Molecular and Cellular Cardiology, 74, 13–21.
12. Wettinger, S. B., Doggen, C. J., Spek, C. A., Rosendaal, F. R., & Reitsma, P. H. (2005). High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood, 105(5), 2000–2006.
13. Small, E. M., & Olson, E. N. (2011). Pervasive roles of microRNAs in cardiovascular biology. Nature, 469(7330), 336–342.
14. van Rooij, E., Marshall, W. S., & Olson, E. N. (2008). Toward MicroRNA–based therapeutics for heart disease the sense in antisense. Circulation Research, 103(9), 919–928.
15. Frost, R. J., & van Rooij, E. (2010). miRNAs as therapeutic targets in ischemic heart disease. Journal of Cardiovascular Translational Research, 3(3), 280–289.
16. Lewis, D. A., Stashenko, G. J., Akay, O. M., Price, L. I., Owzar, K., et al. (2011). Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thrombosis Research, 128(6), 536–540. doi:10.1016/j.thromres.2011.06.003.
17. Qin, J., Liang, H., Shi, D., Dai, J., Xu, Z., et al. (2015). A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. Journal of Thrombosis and Thrombolysis, 39(2), 215–221. doi:10.1007/s11239-014-1131-0.
18. Julià, A., Erra, A., Palacio, C., Tomas, C., Sans, X., et al. (2009). An eight-gene blood expression profile predicts the response to Infliximab in rheumatoid arthritis. PLoS ONE, 4(10), e7556. doi:10.1371/journal.pone.0007556.
19. Khot, U. N., Khot, M. B., Bajzer, C. T., et al. (2003). Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 290(7), 898–904. doi:10.1001/jama.290.7.898.
20. Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., et al. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97(18), 1837–1847. doi:10.1161/01.cir.97.18.1837.
21. Lloyd-Jones, D. M., Nam, B., D’Agostino, R. B., Sr., et al. (2004). Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA, 291(18), 2204–2211. doi:10.1001/jama.291.18.2204.
22. Murabito, J. M., Pencina, M. J., Nam, B., et al. (2005). SIbling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA, 294(24), 3117–3123. doi:10.1001/jama.294.24.3117.
23. Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., et al. (2013). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. doi:10.1161/01.cir.0000437741.48606.98.
24. Ridker, P., Buring, J. E., Rifai, N., & Cook, N. R. (2007). Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA, 297(6), 611–619. doi:10.1001/jama.297.6.611.
25. Cook, N. R., Paynter, N. P., Eaton, C. B., Manson, J. E., Martin, L. W., et al. (2012). Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic women’s health initiative. Circulation, 125(14), 1748–1756. doi:10.1161/circulationaha.111.075929.
26. Blankenberg, S., Zeller, T., Saarela, O., Havulinna, A. S., Kee, F., et al. (2010). Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation, 121(22), 2388–2397. doi:10.1161/circulationaha.109.901413.
27. Melander, O., Newton-Cheh, C., Almgren, P., et al. (2009). Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA, 302(1), 49–57. doi:10.1001/jama.2009.943.
28. Brindle, J. T., Antti, H., Holmes, E., Tranter, G., Nicholson, J. K., et al. (2002). Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nature Medicine, 8(12), 1439–1445.
29. Mäkinen, V.-p., Soininen, P., Forsblom, C., Parkkonen, M., Ingman, P., et al. (2008). 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Molecular Systems Biology, 4, 167. doi:10.1038/msb4100205.
30. Lodovici, M., Luceri, C., De Filippo, C., Romualdi, C., Bambi, F., et al. (2007). Smokers and passive smokers gene expression profiles: correlation with the DNA oxidation damage. Free Radical Biology and Medicine, 43(3), 415–422. doi:10.1016/j.freeradbiomed.2007.04.018.
31. Lampe, J. W., Stepaniants, S. B., Mao, M., Radich, J. P., Dai, H., et al. (2004). Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke. Cancer Epidemiology, Biomarkers & Prevention, 13(3), 445–453.
32. Beineke, P., Fitch, K., Tao, H., Elashoff, M. R., Rosenberg, S., et al. (2012). A whole blood gene expression-based signature for smoking status. BMC Medical Genomics, 5(1), 58.
33. Hopkins, P. N. (2013). Molecular Biology of Atherosclerosis 93. vol 3. doi:10.1152/physrev.00004.2012.
34. Misu, H., Takamura, T., Matsuzawa, N., Shimizu, A., Ota, T., et al. (2007). Genes involved in oxidative phosphorylation are coordinately upregulated with fasting hyperglycaemia in livers of patients with type 2 diabetes. Diabetologia, 50(2), 268–277. doi:10.1007/s00125-006-0489-8.
35. Takamura, T., Honda, M., Sakai, Y., Ando, H., Shimizu, A., et al. (2007). Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. Biochemical and Biophysical Research Communications, 361(2), 379–384. doi:10.1016/j.bbrc.2007.07.006.
36. Ma, J., Dempsey, A. A., Stamatiou, D., Marshall, K. W., & Liew, C.-C. (2007). Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis, 191(1), 63–72. doi:10.1016/j.atherosclerosis.2006.05.032.
37. Freedman, J. E., Larson, M. G., Tanriverdi, K., O’Donnell, C. J., Morin, K., et al. (2010). Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation, 122(2), 119–129. doi:10.1161/circulationaha.109.928192.
38. Grayson, B. L., Wang, L., & Aune, T. M. (2011). Peripheral blood gene expression profiles in metabolic syndrome, coronary artery disease and type 2 diabetes. Genes and Immunity, 12(5), 341–351.
39. Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., et al. (2010). Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circulation Research, 107(6), 810–817.
40. Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., et al. (2010). Circulating microRNAs in patients with coronary artery disease. Circulation Research, 107(5), 677–684. doi:10.1161/circresaha.109.215566.
41. Hoekstra, M., van der Lans, C. A., Halvorsen, B., Gullestad, L., Kuiper, J., et al. (2010). The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochemical and Biophysical Research Communications, 394(3), 792–797.
42. Sondermeijer, B. M., Bakker, A., Halliani, A., de Ronde, M. W. J., Marquart, A. A., et al. (2011). Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS ONE, 6(10), e25946. doi:10.1371/journal.pone.0025946.
43. Becker, D. M., Segal, J., Vaidya, D., et al. (2006). SEx differences in platelet reactivity and response to low-dose aspirin therapy. JAMA, 295(12), 1420–1427. doi:10.1001/jama.295.12.1420.
44. Shen, H., Herzog, W., Drolet, M., Pakyz, R., Newcomer, S., et al. (2009). Aspirin resistance in healthy drug-naïve men versus women (From the Heredity and Phenotype Intervention [HAPI] Heart Study). The American Journal of Cardiology, 104(4), 606–612. doi:10.1016/j.amjcard.2009.04.027.
45. Johnson, A. D., Yanek, L. R., Chen, M.-H., Faraday, N., Larson, M. G., et al. (2010). Genome-wide meta-analyses identifies 7 loci associated with platelet aggregation in response to agonists. Nature Genetics, 42(7), 608–613. doi:10.1038/ng.604.
46. Voora, D., Cyr, D., Lucas, J., Chi, J.-T., Dungan, J., et al. (2013). Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. Journal of the American College of Cardiology, 62(14), 1267–1276. doi:10.1016/j.jacc.2013.05.073.
47. Rosenberg, S., Elashoff, M. R., Beineke, P., Daniels, S. E., Wingrove, J. A., et al. (2010). Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Annals of Internal Medicine, 153(7), 425–434. doi:10.1059/0003-4819-153-7-201010050-00005.
48. Thomas, G. S., Voros, S., McPherson, J. A., Lansky, A. J., Winn, M. E., et al. (2013). A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study. Circulation. Cardiovascular Genetics, 6(2), 154–162. doi:10.1161/circgenetics.112.964015.
49. Taurino, C., Miller, W., Mcbride, M., McClure, J., Khanin, R., et al. (2010). Gene expression profiling in whole blood of patients with coronary artery disease. Clinical Science (London), 119, 335–343.
50. Wingrove, J. A., Daniels, S. E., Sehnert, A. J., Tingley, W., Elashoff, M. R., et al. (2008). Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circulation. Cardiovascular Genetics, 1(1), 31–38. doi:10.1161/circgenetics.108.782730.
51. Calverley, D. C., Casserly, I. P., Choudhury, Q. G., Phang, T. L., Gao, B., et al. (2010). Platelet gene expression as a biomarker risk stratification tool in acute myocardial infarction: A pilot investigation. Clinical Medicine Insights: Blood Disorders 2010 (2193-CMBD-Platelet-Gene-Expression-as-a-Biomarker-Risk-Stratification-Tool-in-Ac.pdf):9.
52. Healy, A. M., Pickard, M. D., Pradhan, A. D., Wang, Y., Chen, Z., et al. (2006). Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation, 113(19), 2278–2284. doi:10.1161/circulationaha.105.607333.
53. Kiliszek, M., Burzynska, B., Michalak, M., Gora, M., Winkler, A., et al. (2012). Altered gene expression pattern in peripheral blood mononuclear cells in patients with acute myocardial infarction. PLoS One, 7(11), e50054. doi:10.1371/journal.pone.0050054.
54. Cheng, Y., Tan, N., Yang, J., Liu, X., Cao, X., et al. (2010). A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clinical Science (London), 119(2), 87–95. doi:10.1042/CS20090645.
55. Gidlöf, O., Andersson, P., van der Pals, J., Götberg, M., & Erlinge, D. (2011). Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology, 118(4), 217–226.
56. D’Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., et al. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. European Heart Journal, 31(22), 2765–2773. doi:10.1093/eurheartj/ehq167.
57. Cheng, Y., Wang, X., Yang, J., Duan, X., Yao, Y., et al. (2012). A translational study of urine miRNAs in acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 53(5), 668–676.
58. Eitel, I., Adams, V., Dieterich, P., Fuernau, G., de Waha, S., et al. (2012). Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. American Heart Journal, 164(5), 706–714.
59. Zampetaki, A., Willeit, P., Tilling, L., Drozdov, I., Prokopi, M., et al. (2012). Prospective study on circulating microRNAs and risk of myocardial infarction. Journal of the American College of Cardiology, 60(4), 290–299. doi:10.1016/j.jacc.2012.03.056.
60. Olivieri, F., Antonicelli, R., Lorenzi, M., D’Alessandra, Y., Lazzarini, R., et al. (2013). Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. International Journal of Cardiology, 167(2), 531–536. doi:10.1016/j.ijcard.2012.01.075.
61. Widera, C., Gupta, S. K., Lorenzen, J. M., Bang, C., Bauersachs, J., et al. (2011). Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. Journal of Molecular and Cellular Cardiology, 51(5), 872–875. doi:10.1016/j.yjmcc.2011.07.011.
62. Long, G., Wang, F., Duan, Q., Yang, S., Chen, F., et al. (2012). Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. PLoS ONE, 7(12), e50926. doi:10.1371/journal.pone.0050926.
63. Meder, B., Keller, A., Vogel, B., Haas, J., Sedaghat-Hamedani, F., et al. (2011). MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Research in Cardiology, 106(1), 13–23. doi:10.1007/s00395-010-0123-2.
64. Kuwabara, Y., Ono, K., Horie, T., Nishi, H., Nagao, K., et al. (2011). Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circulation. Cardiovascular Genetics, 4(4), 446–454. doi:10.1161/circgenetics.110.958975.
65. Wang, G.-K., Zhu, J.-Q., Zhang, J.-T., Li, Q., Li, Y., et al. (2010). Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. European Heart Journal, 31(6), 659–666.
66. Wang, R., Li, N., Zhang, Y., Ran, Y., & Pu, J. (2011). Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Internal Medicine, 50(17), 1789–1795.
67. Devaux, Y., Vausort, M., Goretti, E., Nazarov, P. V., Azuaje, F., et al. (2012). Use of circulating microRNAs to diagnose acute myocardial infarction. Clinical Chemistry, 58(3), 559–567.
68. Ai, J., Zhang, R., Li, Y., Pu, J., Lu, Y., et al. (2010). Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochemical and Biophysical Research Communications, 391(1), 73–77.
69. Adachi, T., Nakanishi, M., Otsuka, Y., Nishimura, K., Hirokawa, G., et al. (2010). Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clinical Chemistry, 56(7), 1183–1185.
70. De Rosa, S., Fichtlscherer, S., Lehmann, R., Assmus, B., Dimmeler, S., et al. (2011). Transcoronary concentration gradients of circulating microRNAs. Circulation, 124(18), 1936–1944.
71. Oerlemans, M. I., Mosterd, A., Dekker, M. S., de Vrey, E. A., van Mil, A., et al. (2012). Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Molecular Medicine, 4(11), 1176–1185.
72. Huang, S., Chen, M., Li, L., He, M., Hu, D., et al. (2014). Circulating microRNAs and the occurrence of acute myocardial infarction in Chinese populations. Circulation. Cardiovascular Genetics. doi:10.1161/circgenetics.113.000294.
73. Vogel, B., Keller, A., Frese, K. S., Kloos, W., Kayvanpour, E., et al. (2013). Refining diagnostic microRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction. Clinical Chemistry, 59(2), 410–418.
74. Jansen, F., Yang, X., Proebsting, S., Hoelscher, M., Przybilla, D., et al. (2014). MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. Journal of the American Heart Association, 3(6), e001249. doi:10.1161/jaha.114.001249.
75. Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., et al. (2014). 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 64(24), e139–e228. doi:10.1016/j.jacc.2014.09.017.
76. Willeit, P., Zampetaki, A., Dudek, K., Kaudewitz, D., King, A., et al. (2013). Circulating microRNAs as novel biomarkers for platelet activation. Circulation Research, 112(4), 595–600.
77. de Boer, H. C., van Solingen, C., Prins, J., Duijs, J. M., Huisman, M. V., et al. (2013). Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. European Heart Journal:eht007.
78. Zhang, Y.-Y., Zhou, X., Ji, W.-J., Shi, R., Lu, R.-Y., et al. (2014). Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 38(1), 65–72.
79. Kaudewitz, D., Lee, R., Willeit, P., McGregor, R., Markus, H. S., et al. (2013). Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thrombosis and Haemostasis, 110(3), 609–615.
80. Chyrchel, B., Totoń-Żurańska, J., Kruszelnicka, O., Chyrchel, M., Mielecki, W., et al. (2014). Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets. doi:10.3109/09537104.2014.974527.
81. Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 361(11), 1045–1057. doi:10.1056/NEJMoa0904327.
82. Voora, D., & Ginsburg, G. S. (2012). Clinical application of cardiovascular pharmacogenetics. Journal of the American College of Cardiology, 60(1), 9–20. doi:10.1016/j.jacc.2012.01.067.
83. Temesvari, M., Kobori, L., Paulik, J., Sarvary, E., Belic, A., et al. (2012). Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. The Journal of Pharmacology and Experimental Therapeutics, 341(1), 294–305. doi:10.1124/jpet.111.189597.
84. Furukawa, M., Nishimura, M., Ogino, D., Chiba, R., Ikai, I., et al. (2004). Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Science, 95(6), 520–529.
85. Minami, Y., Satoh, M., Maesawa, C., Takahashi, Y., Tabuchi, T., et al. (2009). Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. European Journal of Clinical Investigation, 39(5), 359–367.
86. Takahashi, Y., Satoh, M., Minami, Y., Tabuchi, T., Itoh, T., et al. (2010). Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clinical Science (London), 119, 395–405.
87. Devaux, Y., Bousquenaud, M., Rodius, S., Marie, P.-Y., Maskali, F., et al. (2011). Transforming growth factor β receptor 1 is a new candidate prognostic biomarker after acute myocardial infarction. BMC Medical Genomics, 4(1), 83.
88. Matsumoto, S., Sakata, Y., Suna, S., Nakatani, D., Usami, M., et al. (2013). Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circulation Research, 113(3), 322–326.
89. Zile, M. R., Mehurg, S. M., Arroyo, J. E., Stroud, R. E., DeSantis, S. M., et al. (2011). Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circulation. Cardiovascular Genetics, 4(6), 614–619. doi:10.1161/circgenetics.111.959841.
90. Matsumoto, S., Sakata, Y., Nakatani, D., Suna, S., Mizuno, H., et al. (2012). A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochemical and Biophysical Research Communications, 427(2), 280–284.
91. Gidlöf, O., Smith, J. G., Miyazu, K., Gilje, P., Spencer, A., et al. (2013). Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovascular Disorders, 13(1), 12.
92. van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences, 103(48), 18255–18260. doi:10.1073/pnas.0608791103.
93. Dickinson, B. A., Semus, H. M., Montgomery, R. L., Stack, C., Latimer, P. A., et al. (2013). Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. European Journal of Heart Failure, 15(6), 650–659. doi:10.1093/eurjhf/hft018.
94. Akat, K. M., Moore-McGriff, D. V., Morozov, P., Brown, M., Gogakos, T., et al. (2014). Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proceedings of the National Academy of Sciences, 111(30), 11151–11156. doi:10.1073/pnas.1401724111.
95. Lara-Pezzi, E., Gómez-Salinero, J., Gatto, A., & García-Pavía, P. (2013). The alternative heart: impact of alternative splicing in heart disease. Journal of Cardiovascular Translational Research, 6(6), 945–955.
96. Kittleson, M. M., Ye, S. Q., Irizarry, R. A., Minhas, K. M., Edness, G., et al. (2004). Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation, 110(22), 3444–3451. doi:10.1161/01.cir.0000148178.19465.11.
97. Tilemann, L., Ishikawa, K., Weber, T., & Hajjar, R. J. (2012). Gene therapy for heart failure. Circulation Research, 110(5), 777–793. doi:10.1161/circresaha.111.252981.
98. Marfella, R., Di Filippo, C., Potenza, N., Sardu, C., Rizzo, M. R., et al. (2013). Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non‐responders. European Journal of Heart Failure, 15(11), 1277–1288.
99. Gao, G., Brahmanandam, V., Raicu, M., Gu, L., Zhou, L., et al. (2014). Enhanced risk profiling of implanted defibrillator shocks with circulating SCN5A mRNA splicing variants: a pilot trial. Journal of the American College of Cardiology, 63(21), 2261–2269.
100. Heidecker, B., Kasper, E. K., Wittstein, I. S., Champion, H. C., Breton, E., et al. (2008). Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation, 118(3), 238–246. doi:10.1161/circulationaha.107.756544.
101. Mehra, M. R., Benza, R., Deng, M. C., Russell, S., & Webber, S. (2004). Surrogate markers for late cardiac allograft survival. American Journal of Transplantation, 4(7), 1184–1191. doi:10.1111/j.1600-6143.2004.00485.x.
102. Deng, M. C., Eisen, H. J., Mehra, M. R., Billingham, M., Marboe, C. C., et al. (2006). Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. American Journal of Transplantation, 6(1), 150–160. doi:10.1111/j.1600-6143.2005.01175.x.
103. Van Huyen, J-P. D., Tible, M., Gay, A., Guillemain, R., Aubert, O., et al. (2014). MicroRNAs as non-invasive biomarkers of heart transplant rejection. European Heart Journal:ehu346.
104. Pham, M. X., Teuteberg, J. J., Kfoury, A. G., Starling, R. C., Deng, M. C., et al. (2010). Gene-expression profiling for rejection surveillance after cardiac transplantation. New England Journal of Medicine, 362(20), 1890–1900. doi:10.1056/NEJMoa0912965.
105. Deng, M. C., Elashoff, B., Pham, M. X., Teuteberg, J. J., Kfoury, A. G., et al. (2014). Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation, 97(6), 708.
106. Kobashigawa, J., Patel, J., Azarbal, B., Kittleson, M., Chang, D., et al. (2015). Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial (EIMAGE). Circulation. Heart Failure. doi:10.1161/circheartfailure.114.001658.
107. Zhang, C. (2010). MicroRNAs in vascular biology and vascular disease. Journal of Cardiovascular Translational Research, 3(3), 235–240.
108. Eikmans, M., Rekers, N. V., Anholts, J. D. H., Heidt, S., & Claas, F. H. J. (2013). Blood cell mRNAs and microRNAs: optimized protocols for extraction and preservation. Blood, 121(11), e81–e89. doi:10.1182/blood-2012-06-438887.
109. Koh, W., Pan, W., Gawad, C., Fan, H. C., Kerchner, G. A., et al. (2014). Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. Proceedings of the National Academy of Sciences, 111(20), 7361–7366.
110. Huan, T., Zhang, B., Wang, Z., Joehanes, R., Zhu, J., et al. (2013). A systems biology framework identifies molecular underpinnings of coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(6), 1427–1434. doi:10.1161/atvbaha.112.300112.
111. Joehanes, R., Ying, S., Huan, T., Johnson, A. D., Raghavachari, N., et al. (2013). Gene expression signatures of coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(6), 1418–1426. doi:10.1161/atvbaha.112.301169.
112. Huan, T., Rong, J., Tanriverdi, K., Meng, Q., Bhattacharya, A., et al. (2015). Dissecting the roles of microRNAs in coronary heart disease via integrative genomic analyses. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(4), 1011–1021. doi:10.1161/atvbaha.114.305176.
113. Rosenberg, S., Elashoff, M. R., Beineke, P., Daniels, S. E., Wingrove, J. A., et al. (2010). Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Annals of Internal Medicine, 153(7), 425–434. doi:10.7326/0003-4819-153-7-201010050-00005.